Quantcast

Latest Clinical trial Stories

2014-07-29 08:32:50

PLANTATION, Fla., July 29, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Bryostatin is a potent modulator of the enzyme protein kinase C epsilon (PKCe). In preclinical in vivo models, this effect has been shown to play an important role in slowing or reversing AD and restoring cognition, memory and motor skills. The top-line analysis...

2014-07-28 23:04:08

Transparency Market Research has published a new report titled "Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" to its report store. Browse the full report: http://www.transparencymarketresearch.com/e-clinical-solution-software-market.html. Albany, New York (PRWEB) July 28, 2014 According to a new market report published by Transparency Market Research "E-Clinical Solution Software Market- Global Industry...

2014-07-28 08:29:32

-- Next-generation HNO prodrug targeting severe heart failure was well tolerated and showed hemodynamic activity in a Phase I clinical trial -- CHAPEL HILL, N.C., July 28, 2014 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. The company has now initiated dosing of hospitalized...

2014-07-27 23:01:10

LifeScienceIndustryResearch.com adds “Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on MLD. Dallas, TX (PRWEB) July 27, 2014 Metachromatic leukodystrophy (MLD, also called Arylsulfatase A deficiency) is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of...

2014-07-26 23:01:46

MarketOptimizer.org adds “Multiple Sclerosis Global Clinical Trials Review, H2, 2014” to its store. Inquire before buying at http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=9010. Dallas, TX (PRWEB) July 26, 2014 Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of...

2014-07-25 12:25:15

COSTA MESA, Calif., July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO WCCT Global welcomes Peter Nieto as the new Vice President of Business Development. Peter has been in the pharmaceutical industry for over 30 years in a number of different business development positions with some of the largest CROs in the industry. These positions were primarily related to business development/sales management and marketing. The experience he has obtained over the past 30 years makes him a...

2014-07-25 08:24:56

LUGANO, Switzerland, July 25, 2014 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) has expressed concern that the proposed EU General Data Protection Regulation could make cancer research impossible and add a significant burden to cancer patients and doctors. (Logo: http://photos.prnewswire.com/prnh/20131128/654773 ) The proposed wording -'explicit and specific patient consent' - implies that researchers would have to approach patients and ask...

2014-07-24 23:13:47

DZS Clinical Services announced today that SBI Pharmaceuticals, the leading expert in research, development, and manufacturing of 5-ALA, has entered into a preferred provider agreement with DZS to manage several clinical programs related to the development of 5-ALA. Bound Brook, NJ (PRWEB) July 24, 2014 As part of the long-term strategic approach, DZS expects to manage numerous projects in the MENA region during 2014 with potential global expansion. "We are delighted to have a...

2014-07-24 08:33:56

ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients...

2014-07-24 08:33:44

Based on encouraging progression-free survival data, Lpath extends the study to a second cohort and considers additional proof-of-concept studies SAN DIEGO, July 24, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP(TM) is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'